Drug news
Actelion discointinues setipiprant in Asthma and Allergic Rhinitis
Actelion is discontinuing development of its orally-active CRTH2 antagonist, setipiprant, in asthma (Phase IIb) and seasonal allergic rhinitis (Phase III profiling), after two recently concluded studies did not confirm efficacy findings made in earlier studies.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.